Do you want to read an article? Please log in or register.
Lifitegrast Ophthalmic Solution 5.0% (KH732) for Dry Eye Disease: A randomized, Multicenter, Double-Masked, vehicle-controlled Phase 3 Trial
Dry Eye Disease
RECOMMENDED
Related content
Dry Eye Disease
Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal Studies COMET-2 and COMET-3
Ophthalmology
Pattar GR, Wirta D, Jerkins G, Paauw J, McLaurin EB, Liu A, Evans DG, Kenyon K, Cline N, Gupta PK, Meng I, Senchyna M, COMET-2 and COMET-3 study groups
doi: 10.1016/j.ophtha.2025.09.018
Dry Eye Disease
Efficacy and Safety of SJP-0132 in Patients with Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study
Am J Ophthalmol
Hori Y, Wada T, Omatsu K, SJP-0132 clinical study investigators
doi: 10.1016/j.ajo.2025.11.036
Further Publications
Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials
Ophthalmology
Briceño CA, Idowu OO, Khong JJ, Kuenzel T, Tran AQ, Brittain C, Azumi A, Brockwell L, Ghadiri N, Coronel M, Ruf T, Li D, Salvi M, Garrido-Hermosilla AM, Barteselli G, Ortiz-Perez S, of the SatraGO-1 and SatraGO-2 investigators
doi: 10.1016/j.ophtha.2026.08.039
Retinal Diseases
Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial
Lancet Neurol
Préterre C, Gaultier A, Obadia M, Vignal C, Mourand I, Plat J, Sablot D, Gaudron M, Rodier G, Godeneche G, Urbanczyk C, Marc G, Massardier E, Adam S, Boulanger M, Marcel S, Mechtouff L, Ronzière T, Calvière L, Godard-Ducceschi S, Barbin L, Lebranchu P, Guillon B, THEIA collaborators
doi: 10.1016/S1474-4422(25)00308-4
RECOMMENDED
Macular DiseasesRetinal Diseases
12-month outcomes of photobiomodulation in dry age-related macular degeneration: a prospective multicentre randomised double-masked controlled clinical trial
★ 2
Recommended by
Prof. emer. Dr Josef Flammer, Faculty Member
Br J Ophthalmol
Iovino C, Borrelli E, Coco G, Viggiano P, Boscia F, Hasanreisoglu M, Kesim C, Demirel S, Yanık Ö, Lucisano A, Scorcia V, Vagge A, Nicolò M, Proietti S, Bernabei F, Rothschild PR, Farrant S, Ricardi F, Pellegrini M, Mura M, Cartabellotta A, Giannaccare G, Reibaldi M, Carnevali A
doi: 10.1136/bjo-2025-328389
Further Publications
Time-Varying Effects of Valacyclovir Prophylaxis in the Zoster Eye Disease Study: A Post Hoc Exploratory Analysis of a Randomized Clinical Trial
JAMA Ophthalmol
Warner DB, Lee TF, Troxel AB, Prescott C, Cohen EJ, Jeng BH, ZEDS Trial Research Group
doi: 10.1001/jamaophthalmol.2026.3202
Dry Eye Disease
Defining Discordance between Signs and Symptoms in Dry Eye Disease: Insights from the DRy Eye Assessment and Management (DREAM) Study
Am J Ophthalmol
Matar K, Yu Y, Augello P, Ying GS, Asbell PA, Sayegh RR, DREAM Research Group
doi: 10.1016/j.ajo.2026.02.031
Macular Diseases
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial
Ophthalmology
Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD, PHOTON investigators
doi: 10.1016/j.ophtha.2025.10.028
Retinal DiseasesFurther Publications
Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial
JAMA Ophthalmol
Kay CN, Saad L, DeBartolomeo G, Bressler N, Tsang SH, Stepien K, Bernstein P, Lam BL, Washington I, Gorin MB, TEASE-1 Study Group
doi: 10.1001/jamaophthalmol.2026.3662